We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Industry involvement in breast cancer trials may affect study design, focus and results, according to an article published in the online version of the journal Cancer.
Roche is temporarily suspending recruitment in a study of anemic advanced lung cancer patients receiving chemotherapy after an “imbalance” of deaths across the four arms of the study, the company announced.
Roche sent a letter notifying cardiac transplant healthcare practitioners that it brought an early halt to a clinical trial of its drug CellCept after four heart transplant patients suffered acute rejection.
Women who take estrogen as hormone replacement therapy to counter the effects of menopause may be better off using a transdermal patch than swallowing a pill, according to a recent study.
A clinical investigator recently received an FDA warning letter for implanting his experimental devices in 175 subjects without the proper informed consent forms.
Members of the House Committee on Energy and Commerce requested more information from the FDA regarding its approval of the antibiotic Ketek following a subcommittee hearing on the agency’s drug approval process.
Amgen is facing more bad news regarding possible off-label uses of its drug Aranesp after independent study results pointed to adverse outcomes for a certain class of cancer patients prescribed the drug.
A series of studies comparing drug-eluting stents with bare-metal stents points to an emerging consensus that the longer the drug-eluting devices remain implanted, the greater chances are that patients will develop life-threatening blood clots (thromboses).